The safety of lanreotide for neuroendocrine tumor

Amandeep Godara; Nauman S. Siddiqui; Margaret M. Byrne; Muhammad Wasif Saif

doi:10.1080/14740338.2019.1559294

Back

The safety of lanreotide for neuroendocrine tumor

Journal article

Peer reviewed

The safety of lanreotide for neuroendocrine tumor

Amandeep Godara, Nauman S. Siddiqui, Margaret M. Byrne and Muhammad Wasif Saif

Expert opinion on drug safety, Vol.18(1), pp.1-10

01/02/2019

DOI: 10.1080/14740338.2019.1559294

PMID: 30582380

View Online

Abstract

Introduction: Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor. Its action is mediated by its affinity to somatostatin receptors, especially sst2 and sst5 receptors. Its longer half-life offers the convenience of 4-week dosing over the need for frequent injections of short-acting somatostatin analogues. Areas covered: Lanreotide ATG offers progression-free survival benefit in locally advanced or metastatic neuroendocrine tumor (NET) compared to placebo, reflecting a strong antiproliferative signal. As lanreotide is commonly used for management of NET, it is imperative to recognize and appropriately manage any drug-related toxicities. In this review, we will provide an overview of the toxicity with lanreotide and its management. Expert opinion: Lanreotide is highly effective in managing carcinoid symptoms and has a robust anti-tumor effect in NET. Overall, it is well tolerated with low rates of treatment discontinuation due to toxicity. It's toxicity profile is mostly predictable, and patients should be informed of the transient nature of some of the upfront toxicities.

Gastroenteropancreatic neuroendocrine tumors (GEP-NET)

lanreotide

somatostatin

Details

Title: Subtitle: The safety of lanreotide for neuroendocrine tumor
Creators: Amandeep Godara - Tufts University
Nauman S. Siddiqui - Tufts University
Margaret M. Byrne - Tufts University
Muhammad Wasif Saif - Tufts University
Resource Type: Journal article
Publication Details: Expert opinion on drug safety, Vol.18(1), pp.1-10
Publisher: Taylor & Francis
DOI: 10.1080/14740338.2019.1559294
PMID: 30582380
ISSN: 1474-0338
eISSN: 1744-764X
Language: English
Date published: 01/02/2019
Academic Unit: Internal Medicine
Record Identifier: 9984362309602771

Metrics

10 Record Views

17 Times Cited - Web of Science